» Articles » PMID: 31651855

Prognostic Significance of Middle Paraesophageal Lymph Node Metastasis in Resectable Esophageal Squamous Cell Carcinoma: A STROBE-compliant Retrospective Study

Overview
Specialty General Medicine
Date 2019 Oct 26
PMID 31651855
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lymph node metastasis (LNM) of esophageal squamous cell carcinoma (ESCC) has important prognostic significance. In this study, we examined the correlations between lymph node metastatic sites and prognosis in patients with resectable ESCC.A total of 960 patients who received curative esophagectomy with systemic lymphadenectomy between 1996 and 2014 were included in the retrospective analysis. The Kaplan-Meier method and log-rank test were used to perform the survival analysis. The prognostic significance of LNM site was evaluated by Cox regression analysis.The LNM in middle paraesophageal (P < .001), subcarinal (P < .001), lower paraesophageal (P < .001), recurrent laryngeal nerve (P = .012), paratracheal (P = .014), and perigastric (P < .001) sites were associated with poor prognosis in univariate analysis. In multivariate analysis, only middle paraesophageal LNM (MPLNM, P = .017; HR, 1.33; 95%CI, 1.05-1.67) was the independent factor for worse prognosis. Additionally, patients with MPLNM had a lower 5-year survival rate (15.6%) than those with LNM at other sites. Furthermore, upper or middle tumor location and relatively late pN stage were associated with increased risk of MPLNM.Our findings suggested MPLNM could be a characteristic indicating the worst prognosis. Preoperative examinations should identify the existences of MPLNM, especially on patients with risk factors. And patients with MPLNM should be considered for more aggressive multidisciplinary therapies.

Citing Articles

IL-1β promotes esophageal squamous cell carcinoma growth and metastasis through FOXO3A by activating the PI3K/AKT pathway.

Chen S, Yang Y, Zheng Z, Zhang M, Chen X, Xiao N Cell Death Discov. 2024; 10(1):238.

PMID: 38762529 PMC: 11102492. DOI: 10.1038/s41420-024-02008-0.


Pararespiratory and paradigestive lymph node metastases in esophageal squamous cell carcinoma: predicting survival and refining the N staging system.

Tian D, Jiang K, Yang Y, Yan H, Yu R, Huang H BMC Cancer. 2023; 23(1):695.

PMID: 37488497 PMC: 10367276. DOI: 10.1186/s12885-023-11055-2.


Optimal Range of Lymphadenectomy in Pathological Stage T1 and T2 Esophageal Squamous Cell Carcinoma.

Wu H, Zhuang W, Huang S, Guan X, Zheng Y, Xie Z Front Oncol. 2021; 11:619556.

PMID: 34113556 PMC: 8186312. DOI: 10.3389/fonc.2021.619556.


XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.

Jian J, Li S, Liu L, Zhen L, Yao L, Gan L Int J Mol Med. 2020; 46(1):201-210.

PMID: 32377720 PMC: 7255471. DOI: 10.3892/ijmm.2020.4593.

References
1.
Kunisaki C, Makino H, Kimura J, Oshima T, Fujii S, Takagawa R . Impact of lymph-node metastasis site in patients with thoracic esophageal cancer. J Surg Oncol. 2009; 101(1):36-42. DOI: 10.1002/jso.21425. View

2.
Berger A, Farma J, Scott W, Freedman G, Weiner L, Cheng J . Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005; 23(19):4330-7. DOI: 10.1200/JCO.2005.05.017. View

3.
Hsu P, Lin K, Wang S, Huang C, Wu Y, Hsu W . Preoperative positron emission tomography/computed tomography predicts advanced lymph node metastasis in esophageal squamous cell carcinoma patients. World J Surg. 2011; 35(6):1321-6. DOI: 10.1007/s00268-011-1081-z. View

4.
Mao W, Zheng W, Ling Z . Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 2012; 12(10):2461-6. View

5.
Toba H, Kondo K, Otsuka H, Takizawa H, Kenzaki K, Sakiyama S . Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer. J Med Invest. 2010; 57(3-4):305-13. DOI: 10.2152/jmi.57.305. View